Olutasidenib (FT-2102) in patients with relapsed or refractory IDH1-mutant glioma: A multicenter, open-label, phase Ib/II trial

Overview of attention for article published in Neuro-Oncology, May 2022

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#15 of 4,190)
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (98th percentile)

Mentioned by

news: 44 news outlets
twitter: 5 X users

guideline: 1 clinical guideline source

Readers on

mendeley: 37 Mendeley

So far, Altmetric has seen 45 news stories from 44 outlets.

Rigel Pharmaceuticals Provides Business Update

Le Lézard, 08 Jan 2024

SOUTH SAN FRANCISCO, Calif. "2023 was a year of significant growth across our commercial hematology-oncology portfolio.

Rigel Announces Collaboration with CONNECT to Conduct a Phase 2 Trial of Olutasidenib in Glioma

Stockwatch, 04 Jan 2024

SOUTH SAN FRANCISCO, Calif., Jan. 4, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc.

Rigel Announces Collaboration with CONNECT to Conduct a Phase 2 Trial of Olutasidenib in Glioma

MarketScreener, 04 Jan 2024

SOUTH SAN FRANCISCO, Calif., Jan. 4, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc.

Rigel Announces Collaboration with CONNECT to Conduct a Phase 2 Trial of Olutasidenib in Glioma

FOX31 Denver KDVR-TV, 04 Jan 2024

Please enter a search term. Please enter a search term. News provided by Jan 04, 2024, 8:05 AM ET SOUTH SAN FRANCISCO, Calif.…

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity, including 41 additional news stories.